Bispecific antibody production: How the right expression platform makes the difference

Bispecific antibodies (bsAbs) represent one of the most exciting frontiers in immunotherapeutics. However, their complex architecture presents some challenges for production that can slow down development timelines and delay regulatory approval.

In this white paper, you will learn about:

• Top concerns relating to bispecific antibody production
• The importance of cell line selection for bispecific antibody production
• How Revvity's CHOSOURCE™ expression platform supports the requirements of bispecific antibody production
• Key findings from a vector configuration study for the CHOSOURCE GS KO cell line
• Practical guidance for scientists developing a cell line strategy for bispecific antibodies

The CHOSOURCE™ Platform is available for research, clinical, diagnostic, and commercialization applications, including services, under specific licenses from Revvity.